Haleon PLC has successfully completed a share buyback, repurchasing approximately £315 million worth of shares from Pfizer, which will be canceled as part of their capital allocation strategy. This move accompanies Pfizer's global offering of Haleon shares and reduces Pfizer's stake in Haleon from 32% to approximately 22.6%. CEO Brian McNamara expresses confidence in the company's financial strategy and growth prospects, underscoring the buyback as a demonstration of commitment to delivering shareholder value.